Regina Castaneda, a research fellow in endocrinology at the Mayo Clinic in Jacksonville, Fla, said in a news release.Casteneda noted that previous studies of semaglutide (Ozempic/Wegovy) yielded similar findings.Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications, Castenada said.More women are using hormone therapy to manage menopause symptoms like hot flashes and night sweats, following research that found such therapy didnt increase risk of diseases like breast cancer and heart disease as dramatically as previously thought.Menopause-related hormone changes often result in increased belly fat and decreased muscle mass, as well as changes in metabolism that contribute to weight gain, researchers said in background notes.For the new study, researchers tracked the weight of 120 postmenopausal women prescribed Zepbound
2016;5: e15034
GE2 treatment increases neurogenesis in the dorsal hippocampus depending on sex and diet WD reduced the density of DCX-expressing cells compared to SD ( p = 0.024, Cohens d = 1.309), but only in males, and GE2 treatment normalized the density of DCX-expressing cells under a WD in males ( p = 0.008, Cohens d = 4.023
This condition is particularly concerning for individuals with diabetes, high blood pressure, or cardiovascular diseases, as they are already at a heightened risk for vascular complications
.png)
